CAMBRIDGE, Mass., Aug. 3, 2021 /PRNewswire/ -- Akebia
Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company
with the purpose to better the lives of people impacted by kidney
disease, granted 14 newly-hired employees options to purchase an
aggregate of 95,000 shares of Akebia's common stock on July 30, 2021, as inducements material to each
such employee's entering into employment with Akebia. The options
were granted in accordance with Nasdaq Listing Rule 5635(c)(4).
The options have an exercise price of $2.47 per share, which is equal to the closing
price of Akebia's common stock on the grant date. Each stock option
vests over four years, with 25% of the shares vesting on the first
anniversary of the grant date and the remaining 75% of shares
vesting quarterly thereafter, in each case, subject to the new
employee's continued service with the company. Each stock option
has a 10-year term and is subject to the terms and conditions of
the company's Inducement Award Program and a stock option agreement
covering the grant.
About Akebia Therapeutics
Akebia Therapeutics, Inc. is a fully integrated
biopharmaceutical company with the purpose to better the lives of
people impacted by kidney disease. The Company was founded in 2007
and is headquartered in Cambridge,
Massachusetts. For more information, please visit our
website at www.akebia.com, which does not form a part of this
release.
Akebia Therapeutics Contact
Kristen K. Sheppard, Esq.
ir@akebia.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/akebia-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-301347348.html
SOURCE Akebia Therapeutics